HLS Therapeutics Inc. (OTCMKTS:HLTRF) Short Interest Down 9.1% in March

HLS Therapeutics Inc. (OTCMKTS:HLTRF) was the target of a significant drop in short interest in March. As of March 31st, there was short interest totalling 2,000 shares, a drop of 9.1% from the March 15th total of 2,200 shares. Based on an average daily volume of 100 shares, the short-interest ratio is presently 20.0 days.

Analyst Ratings Changes

Separately, Raymond James lowered their target price on HLS Therapeutics from $6.50 to $5.00 and set a “market perform” rating on the stock in a research report on Monday, March 18th.

HLS Therapeutics Stock Performance

Shares of OTCMKTS HLTRF remained flat at $3.85 during midday trading on Wednesday. 102 shares of the company’s stock were exchanged, compared to its average volume of 1,200. The company’s 50 day moving average price is $3.25 and its 200-day moving average price is $3.35. HLS Therapeutics has a 12-month low of $2.60 and a 12-month high of $4.95.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.